X4 PHARMACEUTICALS, INC Total Liabilities
X4 PHARMACEUTICALS, INC (XFOR) had Total Liabilities of $97.61 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-06
- 2026-06-30: Liabilities $97.61M.
- 2026-03-31: Liabilities $101.83M.
- 2025-12-31: Liabilities $104.17M.
- 2025-09-30: Liabilities $101.94M.
| Period end | Liabilities | Liabilities as first filed |
|---|---|---|
| 2026-06-30 | $97.61M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $101.83M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $104.17M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $101.94M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $101.20M 10-Q · filed 2025-08-08 | |
| 2025-03-31 | $107.07M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $124.30M 10-K · filed 2026-03-17 | |
| 2024-09-30 | $118.54M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $116.16M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $111.15M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $96.16M 10-K · filed 2025-03-26 | |
| 2023-09-30 | $105.70M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $105.86M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $72.73M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $81.53M 10-K · filed 2024-03-21 | |
| 2022-09-30 | $51.56M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $50.95M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $49.91M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $52.76M 10-K · filed 2023-03-21 | |
| 2021-09-30 | $51.84M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $52.45M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $54.10M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $50.07M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $43.42M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $37.65M 10-Q · filed 2020-08-04 | |
| 2020-03-31 | $34.93M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $31.48M 10-K · filed 2021-03-19 | |
| 2019-09-30 | $30.43M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $37.34M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $33.11M 10-Q · filed 2019-05-15 | |
| 2018-12-31 | $21.62M 10-K · filed 2020-03-12 | $14.40M 10-K · filed 2019-03-11 |
| 2018-09-30 | $18.00M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $19.45M 10-Q · filed 2018-08-13 | |
| 2018-03-31 | $20.80M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $22.55M 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |